|Bid||1.3700 x 1800|
|Ask||1.4000 x 21500|
|Day's range||1.3300 - 1.4400|
|52-week range||0.8500 - 4.3200|
|Beta (5Y monthly)||2.14|
|PE ratio (TTM)||N/A|
|Earnings date||06 May 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||7.16|
TherapeuticsMD, Inc.'s (NASDAQ:TXMD): TherapeuticsMD, Inc. operates as a women’s healthcare company in the United...
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, announced today the appointment of James C. D’Arecca as the Company’s Chief Financial Officer, effective June 1, 2020. Mr. D’Arecca succeeds Daniel A. Cartwright, who has retired from his position as the Company’s Chief Financial Officer, also effective June 1, 2020. Mr. Cartwright will remain with the Company as an advisor for a transitional period. Mr. D’Arecca joins TherapeuticsMD with broad experience in corporate and operational finance, most recently as Senior Vice President and Chief Accounting Officer of Allergan plc.
TXMD's CEO to present at BofA Securities 2020 Health Care Conference to be held virtually on May 13 at 9:40 a.m. ET
Thank you for joining us for the TherapeuticsMD First Quarter 2020 Financial Results Conference Call. This morning, TherapeuticsMD issued a press release announcing our first quarter financial results. On today's call from TherapeuticsMD are Chief Executive Officer, Robert Finizio; Chief Commercial Officer, Dawn Halkuff; and Mitchell Krassan, our Chief Strategy and Performance Officer.
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -10.53% and 6.72%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
TXMD releases financial and business results for Q1 2020; Q1 revenue exceeded Wall Street consensus; conference call scheduled for today at 8:30 a.m.
On behalf of the Board of Directors of TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, Chairman Tommy G. Thompson today announced the appointment of Karen L. Ling to the Company’s Board of Directors.
TherapeuticsMD releases COVID-19 business update with contingency plan to be implemented in Q2 and Q3; Q1 revenue expected at more than $11 million
On behalf of the Board of Directors of TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, Chairman Tommy G. Thompson today announced the appointments of Paul Bisaro and Gail Naughton, Ph.D., to the Company’s Board of Directors. The appointments fill two of the vacancies created by the resignations from the Board of Brian Bernick, M.D., John C.K. Milligan, IV and Nicholas Segal. Dr. Bernick will continue to serve as a Co-Founder of TherapeuticsMD on a full-time basis, supporting the Company’s outreach with healthcare providers. Mr. Milligan will continue to serve as the President of TherapeuticsMD on a full-time basis, leading the Company’s infrastructure and critical operations.
TherapeuticsMD, Inc. (NASDAQ:TXMD) just released its latest annual results and things are looking bullish. The overall...
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly...
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 31.58% and 200.33%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
TherapeuticsMD (TXMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.